Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
accepted:
13
02
2024
medline:
27
3
2024
pubmed:
27
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is of utmost importance as achieving adequate antifungal exposure is associated with improved outcome. This study aimed to select and evaluate a model-informed precision dosing strategy for posaconazole. Available population pharmacokinetic models for posaconazole administered as a solid oral tablet were extracted from the literature and evaluated using data from a previously published prospective study combined with data collected during routine clinical practice. External evaluation and selection of the most accurate and precise model was based on graphical goodness-of-fit and predictive performance. Measures for bias and imprecision included mean percentage error (MPE) and normalized relative root mean squared error (NRMSE), respectively. Subsequently, the best-performing model was evaluated for its a posteriori fit-for-purpose and its suitability in a limited sampling strategy. Seven posaconazole models were evaluated using 764 posaconazole plasma concentrations from 143 patients. Multiple models showed adequate predictive performance illustrated by acceptable goodness-of-fit and MPE and NRMSE below ± 10% and ± 25%, respectively. In the fit-for-purpose analysis, the selected model showed adequate a posteriori predictive performance. Bias and imprecision were lowest in the presence of two prior measurements. Additionally, this model showed to be useful in a limited sampling strategy as it adequately predicted total posaconazole exposure from one (non-)trough concentration. We validated an MIPD strategy for posaconazole for its fit-for-purpose. Thereby, this study is an important first step towards MIPD-supported posaconazole dosage optimization with the goal to improve antifungal treatment in clinical practice.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is of utmost importance as achieving adequate antifungal exposure is associated with improved outcome. This study aimed to select and evaluate a model-informed precision dosing strategy for posaconazole.
METHODS
METHODS
Available population pharmacokinetic models for posaconazole administered as a solid oral tablet were extracted from the literature and evaluated using data from a previously published prospective study combined with data collected during routine clinical practice. External evaluation and selection of the most accurate and precise model was based on graphical goodness-of-fit and predictive performance. Measures for bias and imprecision included mean percentage error (MPE) and normalized relative root mean squared error (NRMSE), respectively. Subsequently, the best-performing model was evaluated for its a posteriori fit-for-purpose and its suitability in a limited sampling strategy.
RESULTS
RESULTS
Seven posaconazole models were evaluated using 764 posaconazole plasma concentrations from 143 patients. Multiple models showed adequate predictive performance illustrated by acceptable goodness-of-fit and MPE and NRMSE below ± 10% and ± 25%, respectively. In the fit-for-purpose analysis, the selected model showed adequate a posteriori predictive performance. Bias and imprecision were lowest in the presence of two prior measurements. Additionally, this model showed to be useful in a limited sampling strategy as it adequately predicted total posaconazole exposure from one (non-)trough concentration.
CONCLUSION
CONCLUSIONS
We validated an MIPD strategy for posaconazole for its fit-for-purpose. Thereby, this study is an important first step towards MIPD-supported posaconazole dosage optimization with the goal to improve antifungal treatment in clinical practice.
Identifiants
pubmed: 38532053
doi: 10.1007/s40262-024-01361-8
pii: 10.1007/s40262-024-01361-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–38.
doi: 10.1016/j.cmi.2018.01.002
pubmed: 29544767
Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-30.
Maertens JA, Rahav G, Lee DG, Ponce-de-Leon A, Ramirez Sanchez IC, Klimko N, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499–509.
doi: 10.1016/S0140-6736(21)00219-1
pubmed: 33549194
European Medicines Agency. 2014. Noxafil. Assessment Report. https://www.ema.europa.eu/en/documents/variation-report/noxafil-h-c-610-x-0028-epar-scientific-discussion-extension_en.pdf . Accessed 1 Aug 2023.
Krishna G, Ma L, Martinho M, Preston RA, O’Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725–30.
doi: 10.1093/jac/dks268
pubmed: 22833639
pmcid: 3468079
Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88(1):115–9.
doi: 10.1038/clpt.2010.64
pubmed: 20505665
Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.
doi: 10.1086/508774
pubmed: 17143808
Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15(5):380–93.
doi: 10.1097/00007691-199310000-00005
pubmed: 8249044
Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacometr Syst Pharmacol. 2018;7(12):785–7.
doi: 10.1002/psp4.12353
Wicha SG, Martson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928–41.
doi: 10.1002/cpt.2202
pubmed: 33565627
Van Daele R, Wauters J, Dreesen E, Boelens J, Nulens E, Lormans P, et al. Exposure to intravenous posaconazole in critically ill patients with influenza: a pharmacokinetic analysis of the POSA-FLU study. Mycoses. 2022;65(6):656–60.
doi: 10.1111/myc.13446
pubmed: 35437848
Vanderbeke L, Janssen NAF, Bergmans D, Bourgeois M, Buil JB, Debaveye Y, et al. Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive Care Med. 2021;47(6):674–86.
doi: 10.1007/s00134-021-06431-0
pubmed: 34050768
pmcid: 8164057
Chen L, Krekels EHJ, Heijnen AR, Knibbe CAJ, Bruggemann RJ. An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers. Drugs. 2023;83(1):75–86.
doi: 10.1007/s40265-022-01819-8
pubmed: 36607589
Iwasa T, de Almeida C, Fauchet F, Winchell GA, de Greef R, Hasegawa C, et al. Model-informed dose justifications of posaconazole in Japanese patients for prophylaxis and treatment against fungal infection. J Clin Pharmacol. 2023;63(4):421–34.
doi: 10.1002/jcph.2180
pubmed: 36374235
van Iersel M, Rossenu S, de Greef R, Waskin H. A population pharmacokinetic model for a solid oral tablet formulation of posaconazole. Antimicrob Agents Chemother. 2018;62(7).
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43(6):610–23.
doi: 10.1177/0091270003253624
pubmed: 12817524
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503–12.
doi: 10.1007/BF01060893
pubmed: 7310648
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.
doi: 10.1208/s12248-011-9255-z
pubmed: 21302010
pmcid: 3085712
Brendel K, Comets E, Laffont C, Mentre F. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn. 2010;37(1):49–65.
doi: 10.1007/s10928-009-9143-7
pubmed: 20033477
Faber NKM. Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibration. Chemometr Intell Lab. 1999;49(1):79–89.
doi: 10.1016/S0169-7439(99)00027-1
Mu S, Ludden TM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J Pharmacokinet Pharmacodyn. 2003;30(1):53–81.
doi: 10.1023/A:1023297426153
pubmed: 12800807
Chen L, Krekels EHJ, Dong Y, Chen L, Maertens JA, Blijlevens NMA, et al. Meta-PK analysis of posaconazole upon dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race. Int J Antimicrob Agents. 2023;62(6): 106995.
doi: 10.1016/j.ijantimicag.2023.106995
pubmed: 37806462
Jansen AME, Muilwijk EW, van der Velden W, Maertens JA, Aerts R, Colbers A, et al. Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clin Microbiol Infect. 2022;28(7):1003–9.
doi: 10.1016/j.cmi.2022.01.029
pubmed: 35150880
Pena-Lorenzo D, Rebollo N, Sanchez-Hernandez JG, Zarzuelo-Castaneda A, Vazquez-Lopez L, Otero MJ, et al. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients. Eur J Pharm Sci. 2022;168: 106049.
doi: 10.1016/j.ejps.2021.106049
pubmed: 34699939
Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.
doi: 10.1086/598327
pubmed: 19361301
Huang S, Ding Q, Yang N, Sun Z, Cheng Q, Liu W, et al. External evaluation of published population pharmacokinetic models of posaconazole. Front Pharmacol. 2022;13:1005348.
doi: 10.3389/fphar.2022.1005348
pubmed: 36249756
pmcid: 9561726
Schauwvlieghe A, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, et al. High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. Mycoses. 2020;63(2):122–30.
doi: 10.1111/myc.13028
pubmed: 31660650
Bruggemann RJ, van Luin M, Colbers EP, van den Dungen MW, Pharo C, Schouwenberg BJ, et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother. 2010;65(10):2188–94.
doi: 10.1093/jac/dkq280
pubmed: 20667889